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Background: Over the past decade, advances in cancer treatments have been counterbalanced by a rising number
of immunosuppressed patients with a multitude of new risk factors for infection. Hence, the aim of this study was
to determine risk factors, infectious pathogens in blood and oral cavity of oral cancer patients undergoing different
treatment procedures.
Methods: The present prospective cohort analysis was conducted on the patients undergoing treatment in the
radiotherapy unit of Regional Cancer Institute, Pt. B.D. Sharma University of Health Sciences, Rohtak, Haryana, during
the period of January 2007 to October 2009. Total 186 patients with squamous cell carcinoma of oral cavity were
analyzed in the study. Based on treatment procedures patients were divided into three groups, group I were under
radiotherapy, group II under chemotherapy and group III were of radio chemotherapy together. Clinical isolates
from blood and oral cavity were identified by following general microbiological, staining and biochemical methods.
The absolute neutrophile counts were done by following the standard methods.
Results: Prevalent bacterial pathogens isolated were Staphylococcus aureus, Escherichia coli, Staphylococcus
epidermidis, Pseudomonas aeruginosa, Klebsiella pneumonia, Proteus mirabilis, Proteus vulgaris and the fungal
pathogens were Candida albicans, Aspergillus fumigatus. The predominant gram negative bacteria, Pseudomonas
aeruginosa and Klebsiella pneumonia were isolated from blood of radiotherapy and oral cavity of chemotherapy
treated cases respectively. The predominance of gram positive bacteria (Staphylococcus aureus and Staphylococcus
epidermidis) were observed in blood of chemotherapy, radio chemotherapy cases and oral cavity of radiotherapy,
radio chemotherapy treated cases. Our study also revealed the presence of C. albicans fungi as most significant oral
cavity pathogens in radiotherapy and radio chemotherapy cases.
Conclusion: Gram positive bacteria and Gram negative were reported from the blood of all the three groups of
patients. Oral mucositis played a significant role in oral cavity infection and make patients more prone to
C. albicans infection.Background
Cancer patients remain at substantial risk for developing
serious infections despite significant advances in cancer
therapy and supportive care. The treatment of malignant
conditions with cytotoxic chemotherapy and radiation
therapy has become increasingly effective, but it is asso-
ciated with significant side affects, including toxicities to
haemopoietic and non-haematopoietic tissues. Similarly* Correspondence: yadav1964@rediffmail.com
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reproduction in any medium, provided the orneutropenia is still the most common pre-disposing fac-
tor, it is often superimposed on other immunological
deficits (e.g. impaired cellular or humoral immunity)
each of which is associated with a specific spectrum of
infection. Bacterial infections predominate during the
early phases of a neutropenic episode, whereas fungal
infections occur more often in patients with prolonged
neutropenia [1,2]. Beside neutropenia the chemothera-
peutic agents and therapeutic radiation also disrupt the
mucosal banner of the mouth, leading to severe oral
mucositis, gingivitis, oral candidiasis, cellulitis and viral
mucosal eruptions [3-10]. The oral mucositis orl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acterized by erythema, edema, and mucosal shedding,
which can lead to ulceration and secondary infection
[11,12]. Moreover, the oral cavity infections in cancer
patients usually result from the combination of neutro-
penia and mucositis. In oral cavity infection the oral
micro flora may be subsequently replaced by potentially
pathogenic microorganisms, such as Candida sp., (from
72% to 92%), Candida carriage was reported common in
cancer patients, with C. albicans being the predominant
species in patients who undergo radiotherapy for Head
and neck [13-17]. Oral colonization (up to 93%) and in-
fection (up to 30%) are frequently noted in the patients
[18]. The main reason is that the irradiation-induced
histological changes leading to oral mucositis, together
with salivary quantitative and qualitative changes, have
been reported to facilitate yeast growth [13,19]. Beside
that a possible explanation for the higher predisposition
of irradiated patients to candidosis is due to reduced
phagocytic activity of salivary granulocytes against these
micro-organisms [20].
Similar to oral cavity infection, bloodstream infections
(BSI) also remain serious complications in patients re-
ceiving antineoplastic therapy [21]. Bloodstream infec-
tions (BSIs) occur due to the failure of the immune
system and consequently disseminated the disease. The
frequency of BSI infections, their epidemiology, and
the invading organisms have changed in parallel with the
evolution of medical care, particularly with the emer-
gence of an increasingly ill and immunocompromised
population of hospitalized patients who are often heavily
dependant on medical support and indwelling devices
[22,23]. Currently, slightly more than 50% of BSIs are
hospital acquired [24-28].
So, because of a weakened line of defense in oral can-
cer patients, the present prospective cohort study was
carried out, with the aim of isolation, and identification
of bacterial, fungal colonization from oral cavity and
blood of radiotherapy, chemotherapy and radio chemo-
therapy treated patients. It is also important to be men-
tioned that our study was based on evaluation of
colonization of fungal species only and did not consider
the clinical aspects of the fungal species.
Methods
Study design
The present prospective cohort analysis was conducted
on the patients undergoing treatment in the radiother-
apy unit of Regional Cancer Institute, Pt. B.D. Sharma
University of Health Sciences, Rohtak, Haryana, during
the period of January 2007 to October 2009. A total of
186 patients with squamous cell carcinoma of oral
cavity were analyzed in the study. The present study
was approved by Human Ethical Committee of theUniversity (M.D. University, Rohtak) and written con-
sent was also taken from the patients.
Patient’s population
The patients were divided into three groups depending
on their treatment protocol; each category was having
62 cases. First group patients were radiotherapy treated
(RT) only (total dose of radiotherapy ranging from 51 to
60 grays in dose of 200cGY/day, 5 days a week), second
group patients were given chemotherapy treated (CT)
only (3 or 4 Courses of carboplatin, 5-FU, docetaxel/
methotrexate/cisplatin given after 21 days gap) and third
category patients were given radio chemotherapy simul-
taneously (RCT) (Between irradiation, chemotherapy
courses of paclitaxel, carboplatin and 5-FU given).
Inclusion criteria
About 108 CFU/ml of bacteria and 105 CFU/ml of fungi
cells were considered as pathogenic for the study. The
main predisposing factors that can cause oral cavity and
blood stream infection in the three studied groups were
following:
Bloodstream infection (BSI): BSIs were defined, as
isolation of a recognized pathogen (aerobic bacteria and
fungi) from one or more blood cultures (BCs) that
were unrelated to an infection at another site with, or
without fever or hypotension [29,30].
Oral infection: Oral infection was defined as, isolation
of recognized pathogens (aerobic bacteria and fungi)
from one or more oral swab.
Episodes of BSI: Since any given patients could have a
BSI more than once, so we use the term episode of BSI
for each separate event [29,30].
Episode of bactermia: The isolation of one bactermia
(unimicrobial) or more (polymicrobial) microorganisms
in the same blood culture or in a separate blood culture
obtained within 24–48 hours [29,30].
Neutropenia: Neutropenia was defined as, an ANC of
less than 500 neutrophil/μL that may increase
susceptibility to infection [29. 30].
Fever: Oral temperature of ≥ 38.5°C or more within a
24-hours period after initiation of therapy [29,30].
Anemia: A pathologic deficiency for oxygen-carrying
hemoglobin in the red blood cells. In case of males Hb.
< 14 g/dl and in case of females Hb. < 12 g/dl were
considered as anemic cases [31].
Community acquired infection: Any infection acquired
before, or within 48 hours of admission to hospital and
which was not related to any hospital procedure [29,30].
Nosocomial Infection: Nosocomial infection was
defined as, at least one blood culture positive for
significant pathogens in patients before, or within 48
hours of admission to hospital [29,30].
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catheter related when at least one of following
conditions were, meet (1) Isolation of same pathogens
from catheter tip and blood. (2) Isolation of pathogens
from a blood culture obtained from the catheter, but
not from another blood obtained from peripheral vein
at the same time [29,30].
Oral mucositis: WHO describe oral mucositis into 4
categories, like: grade 0- no change; grade 1 soreness/
erythema; grade 2 erythema, ulcers, can eat solids;
grade 3 ulcers, requires liquid diet only; grade 4
alimentation not possible [30].
Exclusion criteria
Patients were excluded from the study if they had clin-
ical or microbiological evidence of bloodstream infection
of unknown origin. Patients who developed, fever within
24 hours after administration of chemotherapy and fever
subsided within next 24 hours after completion of
chemotherapy were also excluded from study. Common
skin isolates, including Coryneforms and Bacillus species
excluded from analysis. Coagulase negative Staphylococci
(CoNS) were only considered as causative pathogens if
two or more blood samples drawn on separate occasions
showed the growth of the pathogen.
Clinical and laboratory data
The data on patient’s age, sex, underlying cancer, clinical
stage of cancer, medications (antibiotics, cytotoxic drugs),
fever, and exposure to radiotherapy or chemotherapy were
recorded over the preceding 30 days and an invasive pro-
cedure performed over the proceeding 10 days. For every
febrile episode of oral infection and blood cavity infection,
the data on: date of onset, date of admission, sources of in-
fection, presence of venous catheters and period of their
insertion, result of complete blood count, severity and
duration of neutropenia were collected.
Oral cavity specimen handling
Before antibiotics were started, Oral swab were taken by
gently rubbing a sterile cotton swab over the labial mucosa,
tongue and cancerous lesion [32]. The swabs were incu-
bated in sheep blood agar, saboured dextrose agar, maccon-
key agar, nutrient agar, and other selective media for
primary isolation of the pathogens. These plates were than
aerobically incubated for 24–48 hours at 37°C temperature
for bacterial pathogens isolation and for 24–72 hours at
30°C in B.O.D. incubator for fungal species isolation.
Blood Specimen handling
Before antibiotics were started, blood samples (5 ml
each) for cultures were obtained from each patient who
developed, fever within 21 days following radiotherapy,
chemotherapy and radio chemotherapy. One samplesisolated from central venous catheter (if present) and
other from peripheral vein. Blood cultures were drawn
with a sterile system after a sterile pad was placed below
the catheter hub and the hub was disinfected with 10%
povidone–iodine. Blood samples were than transferred
in culture bottles of brain heart infusion broth. Bottles
were incubated at 37°C for 7 days. Simultaneously bot-
tles showing positive growth index from blood culture
were gram stained and sub cultured on sheep blood agar,
saboured dextrose agar, macconkey agar and nutrient
agar, simmon citrate agar and cetrimide agar plates.
These plates were than aerobically incubated for 24–48
hours at 37°C temperature for bacterial pathogens isola-
tion and for 24–72 hours at 30°C in B.O.D. incubator for
fungal species isolation.
Microbial identifications
The bacterial pathogens were identified after appearance
of growth on sub cultured, plates of blood and oral swab
by standard microbiological and biochemical procedures.
These biochemical tests include: Carbohydrates fermen-
tation tests, urease tests, oxidase test, haemolysis of
blood, catalase test, motility tests and growth pathogens
on specific media etc. A preliminary examination of fungal
colony on SDA was done through gram stained, smear,
formation of germ tube, study of micro morphology,
morphology on KOH stained smear, assimilation of car-
bon and nitrogen [33-36].
All isolated pathogens were compared with MTCC
standard strains like S. aureus with MTCC 96 strain, S. epi-
dermidis MTCC 435 strain, P. vulgaris MTCC 426 strain,
P. mirabilis MTCC 425 strain, E. coli MTCC 443 strain,
K. pneumonia MTCC 109 strain, P. aeruginosa MTCC 741
strain, C. albicans 3017 strain and A. fumigatus 2550 strain.
Absolute neutrophils count
The absolute neutrophils count (ANC) was done by
multiplying the total WBC count by percentage of neu-
trophils (segmented + band) [37].
ANC ¼ WBC  percentage of neutrophils
On the basis of ANC the patients were divided into
two categories:
Neutropenia: When ANC was less than 500 (severe
risk of infection).
Non neutropenia: When ANC was more than 500
(moderate risk of infection).
Basic statistical methods
Means values were reported ± standard deviation (SD).
Continuous variables mean values were compared by ‘t’
tests. For independent samples difference in proportion
Table 1 Clinical and demographic data of 186 patients
(62 cases per group)
Group I
-Age in years, (median range) 60 (25–83)
-Underlying disease
Carcinoma of oropharynx 12 (19.3%)
Carcinoma of floor of mouth 14 (22.5%)
Carcinoma of base of tongue 17 (27.4%)
Carcinoma of Tonsil Rt. Side 10 (16.1%)





-Male : Female ratio 45:17
Group II
-Age in years, (median range) 45(30–65)
-Underlying disease
Carcinoma of oropharynx 0
Carcinoma of floor of mouth 16 (25.8%)
Carcinoma of base of tongue 22 (35.4%)
Carcinoma of Tonsil Lt. Side 7 (11.29%)





-Male : Female ratio 47:15
Group III
-Age in years, (median range) 50 (48–65)
-Underlying disease
Carcinoma of oropharynx 13 (20.9%)
Carcinoma of floor of mouth 19 (30.64%)
Carcinoma of base of tongue 30 (48.3%)
Carcinoma of Tonsil Rt. Side 0





-Male : Female ratio. 50:12
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Yates correction) or Fisher’s exact test, when appropri-
ate. All test of significance were two tailed. Alpha was
set at 0.05. For the logistic regression odd ratio with 95%
confidence interval (CI95) were calculated. Univariate
analysis of dichotomous and ordinal variables was per-
formed by using the procedures for matched data seta in
the EpiInfo computer Programme (Epi 6.03: centre for
disease control and prevention, USA). Conventional statis-
tical methods were used to calculate means and standard
deviation with the help of Microsoft excel 2007.
Results
Patients and their characteristics
In this study a total of 186 cases of oral squamous car-
cinoma divided into three groups have been taken into
account. Group I patients had a median age of 60 years
(range 25–83 years), with male- female ratio 45:17.
Group II patients were having a median age of 45 years
(range 30–65 years) with male -female ratio 47:15, and
Group III patients were of median age of 50 years (range
48–65 years) with male -female ratio 50:12. Patients in
all three groups were mainly of IIIrd and IVth clinical
stage of cancer with predominant underlying disease
carcinoma on base of tongue (Table 1).
Oral cavity infection
Predisposing factors of oral cavity infection in three
groups have been shown in Table 2. In group 1 out of 62
patients, 35 (43.75%) clinical febrile episodes were found
in 22 neutropenic and 45 (52.32%) from 40 non-
neutropenic. The most significant risk factors of oral in-
fection were found oral mucositis (grade 4) (P< .05). In
case of group II, between 33 neutropenic cases, 46
(52.8%) febrile episodes of oral infection were isolated
and from 29 non-neutropenic patients, 41(47.12%) epi-
sodes were isolated. And the prevalent significant predis-
posing factor was oral mucositis grade 3 (P< .05). In
case of group III, between 44 neutropenic cases, 67
(63.8%) episodes of oral infection were isolated and from
18 non-neutropenic patients, 38 (36.19%) episodes were
recovered and the most significant risk factor was muco-
sitis grade 4 (P< .001).
The pathogens (%) isolated from oral cavity of all three
groups have been shown in Tables 3. In group 1 out of
80 episodes, 143 pathogens were recovered, 136 patho-
gens were from 87 episodes of group II, and 175 patho-
gens were recovered from 105 episodes of group III.
The prevalent pathogens isolated from all three differ-
ent groups have been shown in Table 3. In group
1C. albicans was the most prevalent and significant fungi
isolated from oral cavity after radiotherapy (P< .001).
Gram positive bacteria were isolated from 6 (27.27%) fe-
brile episodes, in neutropenic patients (13, 21.31%) and innon-neutropenic patients (12, 14.63%). All gram negative
bacteria (E. coil, P. aeruginosa, K. pneumonia, P. mirabilis
and P. vulgaris) were isolated in almost in same number
in oral infection. The polymicrobial episodes in oral infec-
tion were recovered in neutropenic cases (20, 57.14%) and
in non neutropenic cases (5, 11.11%). In group II the oral
infection causing pathogen was gram-negative bacteria
Table 2 Predisposing factors for oral cavity infection in febrile episodes of neutropenic and non- neutropenic patients
in radiotherapy, chemotherapy and radio chemotherapy treated cases
Causative factors Group=1 Group= II Group= III
ANC ANC ANC
<500 ≥500 <500 ≥500 <500 ≥500
Duration of neutropenia >7 4(6.55) 4(4.87) 4(5.06) 4(7.01) 4(4.34) 6(7.22)
P = 0.72 P= .71 P = 0.52
Oral mucositis (grade 0) 3(4.91) 3(3.65) 2(2.53) 4(7.01) 5(5.43) 2(2.40)
P = 0.70 P= .23 P = .44
Oral mucositis (grade 1) 4(6.55) 3(3.65) 3(3.79) 5(8.77) 7(7.60) 6(7.22)
P = 0.45 P = 0.27 P = .84
Oral mucositis (grade 2) 5(8.19) 5(6.09) 4(5.06) 5(8.77) 9(9.78) 4(4.81)
P = .74 P = 0.49 P = .33
Oral mucositis (grade 3) 8(13.11) 8(9.75) 19(24.05) 5(8.77) 11(11.95) 7(8.43)
P = 0.71 P = 0.05* P = .60
Oral mucositis (grade 4) 9(14.75) 25(30.48) 11(13.92) 13(22.80) 32(34.78) 12(14.45)
P< .05* P =0.26 P< .001***
Anemia 4(6.55) 3(3.65) 5(6.32) 3(5.26) 5(5.43) 4(4.81)
P = .45 P = 1 P = 1
Central venous line present 6(9.83) 7(8.53) 9(11.39) 7(12.28) 7(7.60) 15(18.07)
P = .97 P= .91 P = .06
Peripheral line present 5(8.19) 3(3.65) 7(8.86) 5(8.77) 4(4.34) 9(10.84)
P = .28 P = 77 P = .17
Community acquired 6(9.83) 17(20.73) 6(7.59) 3(5.26) 3(3.26) 9(10.84)
P = 0.12 P= .73 P = .09
Nosocomial acquired 7(11.47) 4(4.87) 9(11.39) 3(5.26) 5(5.43) 9(10.84)
P = .20 P= .34 P = 0.29
Note: % had been shown in parenthesis, the value in table shows number of patients, ANC= absolute neutrophil count, ANC of< 500 neutrophil/micro L
(neutropenic), ANC≥ 500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with
ANC> 500 neutrophil/micro L (non-neutropenic). P< .05 * less significant, P< .01 ** significant, P< .001 *** highly Significant.
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ered from 20 neutropenic and 16 non-neutropenic febrile
episodes. K. pneumonia was most prevalent and signifi-
cant gram negative bacteria (P< .05). In gram positive
bacteria S. aureus was the prevalent in neutropenic (18,
22.78%) and nonneutropenic cases (11, 19.29%). The
pathogenic fungi were isolated from neutropenic (11,
13.92%) and non-neutropenic (6, 10.52%) patients. The
polymicrobial infection was recovered from 14 episodes
(30.4%) of 8 (24.24%) neutropenic cases and from 11
(26.8%) episodes of 11 (37.9%) non-neutropenic cases. In
group III, 175 pathogens were isolated from 105 febrile
episodes. The predominant isolated pathogens were gram
positive bacteria recovered, 39 (42.39%) from 28 (53.84%)
episodes of neutropenic and 31 (37.34%) pathogens from
15 (51.72%) episodes of non-neutropenic patients. The
prevalent gram positive bacteria were S. aureus (P< .05)
followed by S. epidermidis (P< .05). The gram-negative
bacteria were isolated in higher amount from non-
neutropenic (29, 34.93%) as compared to neutropenic
cases (22, 23.91%). All gram negative pathogens wereisolated were same in number. C. albicans was significant
isolated fungi (P< .05) recovered from neutropenic
(33.69%), non-neutropenic (27.71%) cases. The Polymicro-
bial pathogens were isolated from 15 (22.38%) episodes
and 9 (23.6%) episodes from non-neutropenic patients.
Blood streams infection
Predisposing factors for blood infection have been
shown in Table 4. In group I out of 62 patients, 35
(43.75%) clinical febrile episodes were found in 22 neu-
tropenic and 45 (52.32%) from 40 non-neutropenic. The
most significant risk factors were found oral mucositis
(grade 4) (P< .01), followed by community acquired in-
fection (P< .05). In case of group II, between 33 neutro-
penic cases, 46 (52.8%) febrile episodes of bloodstream
infection were isolated and from 29 non-neutropenic
patients, 41(47.12%) of febrile episodes were isolated and
no significant risk factor was observed. In case of group
III, out of 44 neutropenic cases, 67 (63.8%) febrile epi-
sodes and out of 18 non-neutropenic patients, 38
(36.19%) of febrile episodes were recovered. The most
Table 3 Predominant pathogens isolated from oral cavity of neutropenic and non-neutropenic patients treated with radiotherapy, chemotherapy and
radiochemotherapy (Group I, II, III)
Pathogens ANC (<500) ANC (>500) ANC (<500) ANC (>500) ANC (<500) ANC (>500)
n= 61 n= 82 OR (95 %C.I) P n= 79 n= 57 OR (95 %C.I) P n= 92 n= 83 OR (95 %C.I) P
(A)Gram+ ive 13(21.3) 12(14.6) 1.58(0.61-4.0) 0.41 25(31.6) 18(31.5) 1.00(0.45-2.2) 0.85 39(42.3) 31(37.3) 1.23(0.6-2.3) 0.59
S. aureus 8(13.1) 6(7.3) 1.60(0.25-10.7) 0.85 18(22.7) 11(19.2) 1.64(0.38-7.2) 0.67 29(31.5) 15(18) 3.09(1.0-9.6) <0.05*
S. epidermidis 5(8.1) 6(7.3) 0.63(0.09-4.0) 0.85 7(8.8) 7(12.28) 0.61(0.14-2.2) 0.67 10(10.8) 16(19.2) 0.32(0.1-0.9) <0.05*
(B)Gram -ive 20(32.9) 18(21.9) 1.25(0.57-2.7) 0.68 43(54.4) 33(57.8) 0.87(0.41-1.8) 0.82 22(23.9) 29(34.9) 0.59(0.2-1.1) 0.15
E. coli 4(6.5) 6(7.3) 0.50(0.09-2.6) 0.46 7(8.8) 8(14.3) 0.61(0.17-2.1) 0.56 6(6.5) 8(9.6) 0.98(0.2-4.0) .77
P. aeruginosa 3(4.9) 4(4.8) 0.62(0.09-4.1) 0.68 5(6.3) 4(7) 0.95(0.20-4.7) 1.00 5(5.4) 7(8.4) 0.92(0.2-4.0) 0.82
K. pneumonia 5(8.1) 5(6.0) 0.87(0.16-4.5) 1 27(34.1) 13(22.8) 2.60(0.93-7.3) < 0.05* 4(4.3) 5(6) 1.07(0.2-5.5) 1
P. mirabilis 5(8.1) 3(3.6) 3(0.41-26.4) 0.40 4(5.0) 6(10.5) 0.46(0.10-2.1) 0.31 4(4.3) 5(6) 1.07(0.2-5.5) 1
P. vulgaris 3(3.8) 0 UN 0.23 0 2(3.5) 0.00(0.00-3.14)6 0.18 3(3.2) 4(4.8) 0.99(0.1-6.1) 1
(C) Fungi 28(45.9) 52(63.4) 0.49(0.24-1.0) < 0.05* 11(13.9) 6(10.5) 1.38(0.43-4.5) 0.74 31(33.6) 23(27.7) 1.33(0.6-2.6) 0.48
C. albicans 28(45.9) 40(48.7) 1.30 (1.12-1.5) < . 001*** 7(8.8) 6(10.5) 0.00(0.00-2.8) 0.23 26(28.2) 23(27.7) 0.00(0.0-1.5) <.05*
A. fumigatus 0 12 UN .02 4(5.0) 0 UN 1.0 5(5.4) 0 UN 1
Note: n = number of pathogens, UN: Undefined, % had been shown in parenthesis, ANC= absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC >500 neutrophil/micro L (non-neutropenic).


















Table 4 Predisposing factors for bloodstream infection in febrile episodes of neutropenic and non- neutropenic
patients in radiotherapy, chemotherapy and radio chemotherapy treated cases
Causative factors Group=1 Group= II Group= III
ANC ANC ANC
<500 ≥500 <500 ≥500 <500 ≥500
Duration of neutropenia >7 5(7.81) 4(4.70) 6(6.6) 4(7.27) 10(8.92) 6(6.31)
P = 0.49 P = 1 P = 0.65
Oral mucositis (grade 0) 5(7.81) 3(3.52) 5(5.55) 4(7.27) 5(4.46) 2(1.78)
P = 0.28 P = .73 P = .45
Oral mucositis (grade 1) 6(9.37) 3(3.52) 2(2.22) 5(9.09) 7(6.25) 6(6.31)
P = 0.17 P = 0.10 P = .78
Oral mucositis (grade 2) 4(6.25) 5(5.88) 4(4.44) 5(9.09) 12(10.71) 4 (4.21)
P = 1 P = 0.30 P = .13
Oral mucositis (grade 3) 5(7.81) 8(9.41) 9(10) 6(10.90) 15(13.39) 7(7.36)
P = 0.78 P = 0.91 P = .23
Oral mucositis (grade 4) 7(10.93) 25(29.41) 11(12.22) 12(21.81) 32(28.57) 12(12.63)
P< .01** P =0.19 P< .001***
Anemia 4(6.25) 3(3.52) 10(11.11) 3(5.45) 9(8.03) 6(6.31)
P = .46 P = .37 P = .83
Central venous line present 8(12.5) 7(8.23) 15(16.6) 5(9.09) 7(6.25) 15(15.78)
P = .56 P = .30 P = .05*
Peripheral line present 5(7.81) 3(3.52) 9(10) 5(9.09) 4(3.57) 10(10.52)
P = .02 P = 91 P = .08
Community acquired 6(9.37) 20(23.52) 6(6.06) 2(3.63) 6(5.35) 11(11.57)
P< .05* P = .71 P = .17
Nosocomial acquired 9(14.06) 4(4.70) 13(14.44) 4(7.27) 5(4.46) 16(16.84)
P = .08 P = .29 P< .001***
Note: % had been shown in parenthesis, the value in table shows number of patients, ANC= absolute neutrophil count, ANC of <500 neutrophil/micro L
(neutropenic), ANC ≥500 neutrophil/micro L (non-neutropenic). P = Probability value with an ANC of <500 neutrophil/micro L (neutropenic) vs. those with ANC
>500 neutrophil/micro L (non-neutropenic). P< .05 * less significant, P< .01 ** significant, P< .001 *** highly Significant.
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fection (P< .001), followed by mucositis grade 4 (P< .001)
and central venous line (P< .05).
The pathogens (%) isolated from blood of all three
groups have been shown in Table 4. During the study a
total of 149 pathogens were recovered from 80 febrile
episodes of BSI from group I, 145 pathogens from 87 fe-
brile episodes from group II and 207 pathogens were
recovered from 105 febrile episodes in group III.
In group I gram negative bacteria were recovered from
16 (57.14%) febrile episodes of patients, in neutropenic 26
(40.62%) and 56 (65.80%) in non-neutropenic patients (P
< .001). P. aeruginosa was the most significant (P< .05)
gram negative bacterium. Gram positive bacteria were iso-
lated from, 8 (28.5%) febrile episodes, 23 (35.93%) in neu-
tropenic patients and 18 (21.17%) in non-neutropenic
patients. C. albicans was predominant in neutropenic 9
(14.06%) and nonneutropenic 6 (7.05%) patients. Out of
all febrile episodes of neutropenic and non- neutropenic,
7 episodes (20%, 15.5%) were polymicrobial. In case of
group II the main pathogens were gram-positive bacteriaisolated in 25 (45.45%) febrile episode of neutropenic
(57.77%), and 26 (40%) febrile episode of non-neutropenic
35 (62.85%) patients. Gram-negative bacteria were isolated,
24 (26.26%) from 10 (25%) febrile episodes in neutropenic
and 22 (40%) from 9 (25.71%) febrile episode in non-
neutropenic patients. Pathogenic fungi isolated from neu-
tropenic and non-neutropenic patients were 14 (15.5) and
8 (14.54%). A total of 5 cases (15.15%) in 6 episodes
(13.04) were polymicrobial in neutropenic patients and 4
cases (13.7%) in 6 episodes (14.6%) were in non-
neutropenic cases. In case of group III 207 pathogens were
isolate from 105 febrile episodes. Out of 37 febrile episodes
of neutropenic and 17 febrile episodes of non neutropenic
cases the most significant isolated pathogen (P< .01) were
gram-positive bacteria. The gram-negative bacteria were
found higher in nonneutropenic cases (42, 44.21%) as
compared to neutropenic cases 39 (34.82%). The fungi iso-
lated from neutropenic patients, 10.71% and 18.94% from
non-neutropenic patients. The polymicrobial BSI infection
was reported from 16 episodes (23.8%) of neutropenic and
12 episodes, (31.5%) of non neutropenic patients.
Table 5 Predominant pathogens isolated from blood of neutropenic and non-neutropenic patients treated with radiotherapy, chemotherapy and radio-
chemotherapy (Group I, II. III)
Pathogens ANC (<500) ANC (>500) ANC (<500) ANC (>500) ANC (<500) ANC (>500)
n = 64 n= 85 OR (95 %C.I) P n = 90 n= 55 OR (95 %C.I) P n = 112 n= 95 OR (95 %C.I) P
(A)Gram+ ive 23(35.9) 18(21.1) 2.09(0.95-4.6) 0.07 52(5.7) 25(45.4 1.64(0.7-3.4) 0.20 61( 54.4) 35(36.8) 2.0(1.1-3.7) < 0.01**
S. aureus 15(23.4) 12(14.1) 0.94(0.21-4.1) 0.81 42(4.6) 11(2) 5.35 (1.6-17.6) < .001** 21( 18.7) 28(29.4) 0.1(0.0-0.3) < .001***
S. epidermidis 8(12.5) 6(7.0) 1.07(0.24-4.7) 0.81 10(1.1) 14(25.4) 0.19(0.0-0.6) < .001** 40(35.7) 7(7.3) 7.6(2.6-23.1) < .001***
(B)Gram -ive 26(40.6) 56(65.8) 0.35(0.1-0.7) < 0.001*** 24(2.6) 22(4) 0.55(0.2-1.1) 0.13 39(34.8) 42(44.2) 0.67(0.3-1.2) 0.21
E. coli 10(15.6) 9(10.5) 0.34(0.1-0.9) 0.04 7(7.7) 6(10.9) 1.10(0.2-4.7) 0.85 11(9.8) 17(17.8) 0.58(0.2-1.6) 0.35
P. aeruginosa 6(9.3) 28(32.9) 0.30(0.0-0.9) < 0.05* 7(7.7) 7(12.7) 0.88(0.2-3.7) 0.90 12(10.7) 12(12.6) 1.11(0.3-3.2) 0.97
K. pneumonia 5(7.8) 14(16.4) 0.71(0.1-2.5) 0.76 6(6.6) 5(9.0) 1.13(0.2-5.4) 0.86 10(8.9) 7(7.3) 1.72(0.5-5.8) 0.47
P. mirabilis 5(7.8) 5(5.8) 2.43(0.5-11.1) 0.27 4(4.4) 3(5.4) 1.27(0.2-8.4) 1.00 4(3.5) 5(5.2) 0.85(0.1-4.0) 1
P. vulgaris 0 0 0 0 0 1(1.8) 0.00(0.0-16.4) 0.47 2(1.7) 1(1.0) 1.84(0.1-53.7) 1
(C) Fungi 15(23.4) 11(12.9) 2.06(0.8-5.2) 0.14 14(15. 5) 8(14.5) 1.20(0.4-3.3) 0.88 12(10.7) 18(18.9) 0.51(0.2-1.2) 0.13
C. albicans 9(14.0) 6(7.0) 1.25(0.2-8.0) 1.00 8(8.8) 5(9.0) 0.80(0.0-6.5) 1.00 7(6.2) 10(10.5) 1.12(0.2-6.3) 0.82
A. fumigatus 6(9.3) 5(5.8) 0.80(0.1-5.0) 1.00 6(6.6) 3(5.4) 1.25(0.1-10.5) 1.00 5(4.4) 8(8.4) 0. 89(0.1-4.9) 0.82
Note: n = number of pathogens, % had been shown in parenthesis, ANC = absolute neutrophil count, ANC of <500 neutrophil/micro L (neutropenic), ANC> 500 neutrophil/micro L (non-neutropenic). P = Probability
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This prospective cohort study is first from Haryana, India
and is based on evaluation of the rate, risk factors and out-
comes of treatment procedures between oral cancer
patients. The present report describes colonization of bac-
terial and fungal infectious pathogens in oral cancer
patients.
The colonization of microorganisms in cancer patients
was found to occur in oropharynx as well as gastrointes-
tinal system, urinary system and airways. Colonization
starts within 48 hours of hospitalization [38]. Number of
studies proved that Neutropenia increases the microbial
colonization [39-41]. Our observation also illustrates
that the colonization of microorganisms was higher in
blood and oral cavity of neutropenic cases after chemo-
therapy, radio chemotherapy.
Nowadays, in most of hospitals, there is a shift of the
microbial spectrum of cancer patients from gram-negative
to gram positive, compared with the predominance of
gram-negative species in the 1960s and 1970s [42-46].
Nevertheless in developing countries there is a different
situation where the predominant pathogens are gram-
negative, the reason maybe the people cannot afford to
give routinely prophylactic oral antibiotics, such as quino-
lones, and use less central lines. The predominance of
gram negative bacteria in developing countries can also be
explained with the help of various studies. A study was
conducted on febrile neutropenic patients in a hospital
from Lebanon and observed that the gram-negative bac-
teria were responsible for 78.8% (26/33) of bloodstream
infections compared to 33.3% (11/33) gram-positive
organisms. In the present study dominant gram negative
bacteria were of E. coli and P. aeruginosa. A possible ex-
planation of the observed high incidence of gram-negative
infections in Lebanon was the relatively low proportion of
indwelling catheters [47]. Another study was carried in
Malaysia observed that out of 120 episodes, 60.02% were
gram-negative organisms of Enterobacteriaceae [48]. A
similar pattern of predominant gram-negative bacteria
(61%) was seen in a study of hematologic malignancy
patients from Brazil [49]. Similar to above study we have
also observed that main pathogen isolated from blood of
group I and oral cavity of group II were of gram negative
bacteria. This may be due to absence of use of catheter as
a routine practice during the period of our analysis.
In our study P. aeruginosa was the main gram negative
bacteria in blood stream and K. pneumonia was in oral
cavity. Similar to our study the presence of P. aeruginosa
as an infectious pathogen was also observed by Raje et al.,
[50]. They reported P. aeruginosa (28%) as a major patho-
gen in febrile neutropenic patients of acute lymphobalastic
leukemia cases. Karim et al., [51] and Saghie et al., [52]
were also observed presence of P. aeruginosa in 31% and
38% respectively from febrile neutropenic cases. Howeverour study showed the proportion of P. aeruginosa was
higher in non- neutropenic cases.
The present report also revealed the predominance of
gram positive bacteria (S. aureus and S. epidermidis) in
blood of group II, III and oral cavity of I, III group. The pre-
dominance of gram positive bacteria as infectious pathogen
was also proved by other studies did in India. Jagarmuldi
et al., [43] conducted a study on acute leukemia cases and
observed 38.5% of S. aureus infection in 240 febrile epi-
sodes and in other study S. aureus (39%) infection was
observed in blood after chemotherapy [53]. The prevalence
of gram positive bacteria may be due to that oral cancer pa-
tient were undergone treatment of high intensive chemo-
therapy, radio chemotherapy which may be led to damage
of the mucosal barriers and increases the risk of infection
with gram-positive oral (and GI) flora [54]. In favor of that
reason, we observed the significant predisposing factor for
blood stream infection was the use of central venous line
(P< .05) in group III, which may be facilitated the entry of
organisms colonizing the skin into the bloodstream, and
thus increase the rate of Staphylococcal infections in blood
and oral cavity [2,43]. Our study also observed another
significant predisposing factor of bloodstream infection in
group III was nosocomial acquired (P< .01). The role of
nosocomial acquisition of S. aureus infection was also
demonstrated in various studies did at five centers in
Egypt and a provincial hospital in north east Thailand
[55,56]. Nosocomial infection of S. aureus in developing
countries is probably common, the reasons for which may
include lack of hand washbasins or hand washing, over-
crowding in hospital wards and clinics, lack of infection
control training or policies, the inability to isolate specific
patients, and lack of diagnostic microbiology facilities [56].
Another salient featured of our study was the
colonization of C. albicans as most significant oral cavity
pathogens in group I and III patients. C. albicans was iso-
lated in group I neutropenic, non neutropenic cases in
proportion of 45.90%, 48.78% respectively and in group III
its proportion in neutropenic, non neutropenic cases was
28.2%, 27.72% respectively. The proportion of C. albicans
in group I i.e. radiotherapy treated, cases was similar to
various studies conducted on oral candidiasis after radio-
therapy and showed a wide variation ranging from 17 to
52.5% [4,17,19,57-60]. The colonization of C. albicans in
oral cavity of radiotherapy treated, cases may be due to
the reason that our patients were often unable to maintain
satisfactory oral health and nutritional status during RT,
mainly because of low income and educational level. This
reasons of colonization of C. albicans in oral cavity was
also observed in study did in Brazilian patients undergoing
head and neck radiotherapy [17]. The pathogenesis of can-
didal infections is complex encompassing both fungi and
host factors. Candidal colonisaion appears to be influenced
by adherence mechanisms among fungi and oral
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encourages oral candidal colonization that often leads to
oral candidiasis [19].
We have also observed other reason of colonization of C.
albicans may be oral mucositis, which played a significant
role in oral cavity infection of all three groups. Generally it
is also accepted that oral mucositis, is of multifactorial ori-
gin, and it is ranged among 20% and 100% in patients re-
ceiving different types of cancer treatments [61-65]. Other
reason for the prevalence of mucositis in our study may be
due to fluorinated 5-fluorouracil (5-FU) which was the
most effective and frequently used antineoplastic agent for
the treatment of oral cancer. There are others reports
which also showed mucositis (4 to 74% for head and neck
cancers) induced by 5-FU [66,67].
Some limitations were present in our study, first was
that we did not take the clinical features of Oral candi-
dosis in our patients i.e. we were not able to evaluate
that whether the Oral candiasis remain confined to the
oral cavity, or spread to oesophageal or more widely to
cause systemic candidosis. This study also is limited to
infections caused by aspergillosis and candidiasis. Al-
though these two pathogens represent most of fungal
infections, infections due to other fungal species may re-
sult an additional burden to the oral cancer cases.
Conclusion
Radiotherapy and chemotherapy have been widely used
for the treatment of malignant lesions in oral cancer
patients to increase the survival rates. However, these
therapies are still associated with several adverse reac-
tions that affect patient quality of life significantly, and
may even affect the progress of the treatment. Taking
into account that the occurrences of oral cancer rates
are probably going to be the increase in near future, it is
extremely important that health professionals are famil-
iarized with the complications from anti-neoplastic
treatments. The present study revealed that radio and
chemotherapy treated immunocompromised patients are
prone to bacterial and fungal infection with predomin-
ance of gram positive bacteria. This study also revealed
the presence of C. albicans fungi as most significant oral
cavity pathogens in radiotherapy and radio chemother-
apy treated patients. So the multidisciplinary treatment,
including medical team, dental surgeons, speech thera-
pists, nutritionists and psychologists, is the best option
to minimize or even prevent such complications in oral
cancer cases.
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